Tokyo
London
New York
Tokyo
London
New York
| NASDAQ: ACRS | Healthcare / Biotechnology / USA |
| 15.65 | -0.15 | -0.95% | Vol 169 434 | 1Y Perf -38.04% |
| Aug 17th, 2018 16:00 |
| BID | 15.65 | ASK | 15.67 | ||
| Open | 15.80 | Previous Close | 15.80 | ||
| Pre-Market | - | After-Trading | 15.65 | ||
| - -% | - -% |
| Target Price | 47.00 | Analyst Rating | Strong Buy 1.00 | |
| Potencial % | 200.32 | Finscreener Ranking | — - | |
| Insiders Trans % 3/6/12M | -100/11/11 | Value Ranking | — - | |
| Insiders Value % 3/6/12M | -100/43/43 | Growth Ranking | — - | |
| Insiders Shares Cnt. % 3/6/12M | -100/52/52 | Income Ranking | — - | |
| Market Cap (mil) | 485 | Earnings Rating | — | |
| Price Range Ratio 52wk % | 4.18 | Earnings Date | — |
Today's Price Range 15.4315.95 | 52wk Range 15.0728.93 |
Summary:
Neutral
| Technical Indicators: | Neutral |
| Moving Averages: | Neutral |
| Performance | |||
|---|---|---|---|
| 1 Month | -21.39% | ||
| 3 Months | -19.55% | ||
| 6 Months | -21.51% | ||
| 1 Year | -38.04% | ||
| 3 Years | - | ||
| 5 Years | - |
| Financial Strength | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| Quick Ratio | 8.30 | |||
| Current Ratio | 8.50 | |||
| Long Term Debt to Total Capital | - | |||
| Total Debt to Equity | 0.00 | |||
| Interest Coverage | - | |||
| Leverage Ratio | 1.10 |
| Profitability | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| Gross Margin | 48.20 | |||
| EBIT Margin | -1 653.90 | |||
| EBITDA Margin | -1 641.00 | |||
| Pre-tax Profit Margin | - | |||
| Profit Margin | - |
| Valuation | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| PE Ratio | - | |||
| PB Ratio | 3.08 | |||
| PS Ratios | 97.86 | |||
| Price to Cash Flow | - | |||
| Price to Free Cash Flow | -6.20 | |||
| Cash Flow Per Share | -2.49 | |||
| Price to Tangible Book | 3.61 | |||
| Book Value per Share | 5.62 | |||
| Enterprise Value (in ths.) | 371 913 |
| Management Effectiveness | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| Return on Equity (5Y Avg) | -34.39 | |||
| ROE last 12 Months | -59.92 | |||
| Return on Assets (5Y Avg) | -16.62 | |||
| ROA last 12 Months | -54.18 | |||
| Return on Capital (5Y Avg) | - | |||
| ROC last 12 Months | -59.73 | |||
| Return on invested Capital Q | -16.63 | |||
| Return on invested Capital Y | -34.69 | |||
| Assets Turnover | 0.00 | |||
| Receivables Turnover | 5.00 |
| Revenue | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| Revenue LTM (in ths.) | 5 477 | |||
| Revenue per Share | 0.18 | |||
| Revenue Growth 3 Years | - | |||
| Revenue Growth 5 Years | - |
| Dividends | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| Dividend Yield | - | |||
| Dividend Rate | - | |||
| Dividend Growth 3 Years | - | |||
| Dividend Growth 5 Years | - |
| Earnings History | Estimate | Reported | Surprise % |
|---|---|---|---|
| Q02 2018 | -0.95 | -1.01 | -6.32 |
| Q01 2018 | -0.99 | -0.98 | 1.01 |
| Q04 2017 | -0.90 | -0.80 | 11.11 |
| Q03 2017 | -0.86 | -0.63 | 26.74 |
| Q02 2017 | -0.68 | -0.56 | 17.65 |
| Q01 2017 | -0.54 | -0.48 | 11.11 |
| Q04 2016 | -0.59 | -0.49 | 16.95 |
| Q03 2016 | -0.68 | -0.50 | 26.47 |
| Earnings Per End | Estimate | Revision % | Trend |
|---|---|---|---|
| 6/2018 QR | -0.95 | 78.26 | Positive |
| 9/2018 QR | -1.11 | 60.22 | Positive |
| 12/2018 FY | -4.36 | - | - |
| 12/2019 FY | -3.39 | - | - |
| Next Report Date | 14th Aug 2018 |
| Estimated EPS Next Report | -0.95 |
| Estimates Count | 3 |
| EPS Growth Next 5 Years % | - |
| Volume Overview | |
|---|---|
| Volume | 169 434 |
| Shares Outstanding (in ths.) | 30 980 |
| Trades Count | 830 |
| Dollar Volume | 2 325 097 |
| Avg. Volume | 269 941 |
| Avg. Weekly Volume | 175 187 |
| Avg. Monthly Volume | 236 612 |
| Avg. Quarterly Volume | 242 647 |
| Week | Month | Three Months | Six Months |
|---|---|---|---|
Bearish Bullish 100%0% |
Bearish Bullish 34%66% |
Bearish Bullish 64%36% |
Bearish Bullish 63%37% |
There are no comments yet.
 |  |  |  |  |  |
Copyright (c) 2018. All rights reserved. Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate quotes are realtime. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.com, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
All rights reserved. Financial Market Data powered by Quotemedia.com. All rights reserved. View the Terms of Use. NYSE/NYSE MKT (AMEX) data delayed 20 minutes. NASDAQ and other data delayed 15 minutes unless otherwise indicated. Technology and data provided by TeleTrader. Conditions of Use. The regulations of the respective stock are to be observed. Copyright © 2018. All market data is provided by Barchart Solutions. Futures: at least a 10 minute delay. Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. To see all exchange delays and terms of use, please see disclaimer. The Cryptocurrency Market realtime data provided by Cryptocompare.com
